Stability of trivalent human papillomavirus (types 16, 18, 58) recombinant vaccine (Escherichia coli)

Yu-Ying Liu,Hai-Jiang Zhang,Er-Cui Shen,Dan Chen,Yan Wang,Si-Jia Fu,Fei Yin,Gui-Feng Zhang,Yi-Guo Shen,Yong-Jiang Liu
DOI: https://doi.org/10.1097/cm9.0000000000001659
IF: 6.133
2021-07-19
Chinese Medical Journal
Abstract:To the Editor: There are 530,000 new cases of cervical cancer and 270,000 deaths annually in the world, 85% occur in developing countries. Among them, about 150,000 new cases of cervical cancer are in China each year, accounting for one-third of the total patients worldwide.[1] Vaccines are the most economical and effective ways of preventing infectious diseases. To stop the transmission of human papillomavirus (HPV) fundamentally, the most effective measure is to vaccinate safe and effective HPV vaccines.[2,3] Numerous studies have shown that vaccines based on HPV L1 virus-like particles (VLPs) have good safety and protective efficacy.[4] Infection of HPV16, HPV18, and HPV58 viruses is the main cause of cervical cancer in Chinese women. By preventing the infection of HPV16, HPV18, and HPV58 viruses, 85.0% to 93.7% of cervical cancers can be prevented.[5]
medicine, general & internal
What problem does this paper attempt to address?